Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered test aims to predict best cancer treatment for each patient

NCT ID NCT06929338

Not yet recruiting Diagnosis Sponsor: First Ascent Biomedical Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to see if xDRIVE can accurately predict treatment response in at least 80% of the 30 participants. If it works, this could help personalize cancer therapy and avoid ineffective treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

xDRIVE functional precision medicine platform (diagnostic test)

What this could lead to

If successful, this platform could help doctors choose the most effective therapy for each patient, improving outcomes and avoiding ineffective treatments.

What could go wrong

This is a small, early feasibility study with only 30 participants. The platform may not reach the target accuracy, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm colorectal cancer colorectal neoplasm malignant colon neoplasm rectal cancer rectal carcinoma rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLON ADENOCARCINOMA METASTATIC COLON CANCER METASTATIC RECTAL ADENOCARCINOMA METASTATIC RECTAL CARCINOMA METASTATIC RECTUM CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••